Press Releases

Press Releases

September 16, 2019
Data show >90% knockdown of TTR following administration in healthy volunteers Positive safety and tolerability profile for LICA platform-based therapy Phase 3 program on track to start later this year in patients with all forms of TTR amyloidosis BOSTON and CARLSBAD, Calif., Sept.
August 29, 2019
Multiple presentations on the long-term efficacy and safety of TEGSEDI ® (inotersen) in patients with polyneuropathy caused by hATTR Amyloidosis Topline data results to be presented from the Phase 1 study of AKCEA-TTR-L Rx for the treatment of Transthyretin Amyloidosis (TTR) BOSTON and CARLSBAD,
August 7, 2019
Mean triglyceride levels decreased 77% in volanesorsen-treated patients versus an 18% increase in patients in placebo group Ionis Logo Akcea launching WAYLIVRA in the European Union BOSTON and CARLSBAD, Calif, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.
August 6, 2019
Achieved Second Quarter 2019 TEGSEDI ® (inotersen) Global Net Product Revenues of $10 Million Conference Call Webcast Tuesday, August 6 , 4:30 p.m. ET at  www.akceatx.com BOSTON , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
August 6, 2019
Study meets primary and key secondary endpoints BOSTON, Mass. and CARLSBAD, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today topline results from the
July 29, 2019
Webcast scheduled for Tuesday, August 6th at 4:30 p.m. Eastern Time BOSTON , July 29, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , announced today that it will host a live webcast on Tuesday, August 6 th at 4:30 p.m.
July 16, 2019
Akcea and Ambry Genetics grow partnership, providing easily accessible, no-cost, confidential genetic testing and genetic counseling services to people with suspected hereditary ATTR amyloidosis BOSTON and Aliso Viejo, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.
June 26, 2019
Multiple clinical presentations focus on the long-term clinical benefits of treatment with TEGSEDI® (inotersen) BOSTON and CARLSBAD, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc.
June 20, 2019
Multiple clinical presentations focus on the long-term clinical benefits of treatment with TEGSEDI® (inotersen) BOSTON and CARLSBAD, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc.
May 28, 2019
BOSTON , May 28, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that management will present a company overview at the